Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.470
-0.030 (-1.20%)
At close: Feb 27, 2026, 4:00 PM EST
2.454
-0.016 (-0.66%)
After-hours: Feb 27, 2026, 7:49 PM EST
BDTX Employees
Black Diamond Therapeutics had 24 employees as of December 31, 2024. The number of employees decreased by 30 or -55.56% compared to the previous year.
Employees
24
Change (1Y)
-30
Growth (1Y)
-55.56%
Revenue / Employee
$2,916,667
Profits / Employee
$895,750
Market Cap
140.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 24 | -30 | -55.56% |
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | 69 | 37 | 115.63% |
| Sep 30, 2020 | 58 | 28 | 93.33% |
| Jun 30, 2020 | 49 | 28 | 133.33% |
| Mar 31, 2020 | 37 | 16 | 76.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zentalis Pharmaceuticals | 166 |
| Adagene | 138 |
| Artiva Biotherapeutics | 106 |
| Immunic | 90 |
| Connect Biopharma Holdings | 62 |
| Cardiff Oncology | 31 |
| Genelux | 24 |
| Unicycive Therapeutics | 23 |
BDTX News
- 3 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 3 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout - Seeking Alpha
- 4 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 6 months ago - Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash - Seeking Alpha